The Critical and Chronic Care Products Market in 2020 is estimated at $12,883 million, and it is growing at a CAGR of 6.9% from 2020 to 2025.
The Major Key Players in the market include Piramal, Mylan, Convatec, Novarties, GE Healthcare, Abbott, Plunketts Health Care, Sproxil, safaricom, Dexcom, Walgreens, and Baxter International.
April 2020 the US Food and Drug Administration (FDA) has granted temporary approval for home administration of omalizumab for patients with moderate-to-severe asthma (although not chronic urticaria) in an effort to minimize the need for these high-risk patients to visit a health care facility, although supervised administration remains the preferred approach. July 2020 new, consensus guideline on vancomycin therapeutic monitoring for serious Staphylococcus aureus infection was issued by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacist.
The role of convalescent plasma for treatment of COVID-19 is uncertain, but it may provide a clinical benefit for some patients. Two randomized trials and several observational studies have suggested that convalescent plasma containing high levels of antibodies to SARS-CoV-2 may reduce mortality when given to hospitalized patients early in the course of disease. However, these studies are limited by small size, imprecision, and/or potential confounding factors and some are yet to be peer reviewed. In August 2020, the US Food and Drug Administration (FDA) issued an emergency use authorization for convalescent plasma for patients hospitalized with COVID-19. Convalescent plasma with high antibody levels, administered early in the disease course, is a reasonable option for hospitalized patient.
Piramal Pharma Solutions, a leading contract development and manufacturing organization (CDMO), today announced that it is providing Bolt Biotherapeutics (Bolt) with the supply of both the BDC-1001 ISAC drug substance and the drug product for Bolt’s ongoing Phase 1/2 clinical study in cancer patients. The Piramal Pharma Solutions (PPS) team is applying its integrated drug development model to Bolt’s BDC-1001 for the treatment of patients with HER2-expressed solid tumors. The program encompasses formulation development and ISAC development and manufacture at PPS’ Grangemouth, UK site.
Mylan, a global pharmaceutical company, July 2020 announced that the Drug Controller General of India (DCGI) has approved the anti-tuberculosis drug pretomanid for conditional access under the National Tuberculosis Elimination Program (NTEP) program, making India the second country in the world to provide regulatory approval for this product. Pretomanid has been approved as part of a three-drug, six-month all-oral regimen (with option to extend treatment to nine months in certain conditions) consisting of bedaquiline, pretomanid and linezolid, collectively referred to as “BPaL” for the treatment of adult patients with pulmonary extensively drug-resistant TB (XDR-TB), treatment intolerant or non-responsive multidrug-resistant TB (MDR-TB).
Market segmentation on the basis of product split into Surgical, Pediatric, Psychiatric and others. By application it has Hospitals and Clinics and other. By region it has been splits into North America, Europe, Asia-pacific and Row. In 2020, the United States dominated the Critical Care Equipment Market due to the highest number of COVID-19 affected people. The situation is going to further worsen in some countries like India as the number of affected is increasing day by day. The supply of the ventilator is outnumbering its demand and thus, encouraging manufacturing companies to increase their production.